Revolutionary Myopia Management Technology Expands Across Asia — Kubota Glass Makes Global Debut at ASEAN International Optics Fair Bangkok 2025

Kubota Pharmaceutical Holdings Co., Ltd. (TSE: 4596) has announced the international launch of its innovative myopia management device, Kubota Glass, at the ASEAN International Optics Fair in Bangkok, Thailand, from October 9-11, 2025, reports 24brussels.

With projections indicating that half of the global population will be myopic by 2050, myopia progression in children has become a significant public health issue, particularly in Asia, where prevalence rates are among the highest worldwide. Limited existing treatment options underscore the urgent demand for effective new solutions.

Kubota Glass represents a significant advancement in myopia management, utilizing proprietary AR x optical technology to project actively stimulated defocus onto the retina, effectively suppressing myopia progression. The device is designed for convenience, requiring just two hours of daily wear while adhering to rigorous safety standards compliant with ISO regulations.

“This technology has the potential to transform how we approach myopia management globally,” stated Dr. Ryo Kubota, President and CEO of Kubota Pharmaceutical Holdings. “Our pilot studies have demonstrated remarkable outcomes, and we’re excited to bring this innovation to the Asian market where the need is most acute.”

Kubota Glass features several innovative attributes that distinguish it in the myopia management sector:

• Ultra-lightweight design at just 40g for comfortable daily use
• Smart monitoring capabilities to track usage and treatment compliance
• Non-invasive approach offering an alternative to daily eye drops
• ISO 15004-2 certified safety standards for ophthalmic instruments
• Convenient 2-hour daily wear accommodating busy family schedules

Small-scale pilot studies conducted in the United States and Taiwan have shown promising preliminary results, including a responder rate of up to 92%. Ongoing research is focused on further evaluating the device’s long-term efficacy and safety profile.

The exhibition in Bangkok will provide ophthalmologists, optical retailers, and optometrists throughout ASEAN countries—including Singapore, Malaysia, Taiwan, the Philippines, Vietnam, and Indonesia—with an exclusive opportunity to experience the Kubota Glass technology firsthand.

The early adoption of Kubota Glass not only addresses increasing patient needs but also offers eye care professionals a competitive edge in the rapidly growing optical and ophthalmic markets across Asia. The company is dedicated to accelerating its expansion through strategic partnerships and comprehensive support for practitioners.

Kubota Pharmaceutical Holdings Co., Ltd., along with its subsidiary, Kubota Vision Inc., is committed to advancing a comprehensive portfolio of pharmaceutical and medical device solutions aimed at preserving and restoring vision for millions globally. Under the mission of “Innovation for Vision,” the company is focused on developing next-generation ophthalmic technologies, including advanced myopia management solutions, thereby enhancing quality of life worldwide.

For more information about Kubota Glass and the company’s vision care portfolio, visit www.kubotaholdings.co.jp/en/index.html